GSK says exploring all options to make COVID-19 antibody drug Sotrovimab available in India quickly

Treatment with Sotrovimab resulted in an 85 percent reduction in the risk of hospitalisation or death in high-risk adult COVID-19 outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial.

from Moneycontrol Business News https://ift.tt/3oSe3J0